Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis® Pan-Cancer Strategy

Strategic Review to Include Potential Separation of iCRO, Potential U.S. Listing
and Other Strategic Alternatives